Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Evoke Pharma (EVOK) over the last 5 years, with Q3 2025 value amounting to $101977.0.

  • Evoke Pharma's Cost of Revenue fell 196.78% to $101977.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $429769.0, marking a year-over-year increase of 4467.66%. This contributed to the annual value of $356531.0 for FY2024, which is 7660.63% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Cost of Revenue is $101977.0, which was down 196.78% from $167679.0 recorded in Q2 2025.
  • Over the past 5 years, Evoke Pharma's Cost of Revenue peaked at $190084.0 during Q4 2022, and registered a low of $22760.0 during Q1 2022.
  • For the 5-year period, Evoke Pharma's Cost of Revenue averaged around $82536.4, with its median value being $67774.0 (2022).
  • In the last 5 years, Evoke Pharma's Cost of Revenue tumbled by 6894.85% in 2023 and then skyrocketed by 30426.01% in 2025.
  • Evoke Pharma's Cost of Revenue (Quarter) stood at $136679.0 in 2021, then surged by 39.07% to $190084.0 in 2022, then tumbled by 68.95% to $59024.0 in 2023, then soared by 100.77% to $118500.0 in 2024, then decreased by 13.94% to $101977.0 in 2025.
  • Its Cost of Revenue stands at $101977.0 for Q3 2025, versus $167679.0 for Q2 2025 and $41613.0 for Q1 2025.